| Dr Daniel Robert Possley, DO | |
|
340 Exempla Cir Ste 300, Lafayette, CO 80026-3384 | |
| (303) 673-1390 | |
| (720) 863-7446 |
| Full Name | Dr Daniel Robert Possley |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 17 Years |
| Location | 340 Exempla Cir Ste 300, Lafayette, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184885071 | NPI | - | NPPES |
| 390200000X | Other | TX | STUDENTIN AN ORGANIZED HEALTH CARE EDUCATION/TRAINING PROGRAM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 207X00000X (Colorado) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Medical Center Llc | Lafayette, CO | Hospital |
| Platte Valley Medical Center | Brighton, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Scl Health Medical Group - Denver Llc | 0840513552 | 414 |
News Archive
Patients and their physicians should be careful when selecting a chemotherapy drug to treat colorectal cancer that has spread to the liver, say researchers at The University of Texas M. D. Anderson Cancer Center in Houston.
Some of us who are hospitalized are feeling worse rather than better. On average, seven percent of all patients in industrial countries are affected by "nosocomial" infections. In intensive care units, the risk increases even more. This can result in serious illnesses and life-threatening blood poisoning.
A scientist at Leeds whose research is challenging conventional thinking on how the cholesterol-reducing drugs statins benefit cardiac patients, has secured funding to further investigate her findings.
Alexza Pharmaceuticals, Inc. announced today that it completed an End-of-Review meeting with the U.S. Food and Drug Administration (FDA or Agency) for the AZ-004 New Drug Application (NDA), and has received the official FDA minutes from the meeting. In December 2010, Alexza held the End-of-Review meeting in response to a Complete Response Letter (CRL) received in October 2010.
DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.
› Verified 1 days ago
| Entity Name | Scl Health Medical Group - Denver Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083021083 PECOS PAC ID: 0840513552 Enrollment ID: O20150106000131 |
News Archive
Patients and their physicians should be careful when selecting a chemotherapy drug to treat colorectal cancer that has spread to the liver, say researchers at The University of Texas M. D. Anderson Cancer Center in Houston.
Some of us who are hospitalized are feeling worse rather than better. On average, seven percent of all patients in industrial countries are affected by "nosocomial" infections. In intensive care units, the risk increases even more. This can result in serious illnesses and life-threatening blood poisoning.
A scientist at Leeds whose research is challenging conventional thinking on how the cholesterol-reducing drugs statins benefit cardiac patients, has secured funding to further investigate her findings.
Alexza Pharmaceuticals, Inc. announced today that it completed an End-of-Review meeting with the U.S. Food and Drug Administration (FDA or Agency) for the AZ-004 New Drug Application (NDA), and has received the official FDA minutes from the meeting. In December 2010, Alexza held the End-of-Review meeting in response to a Complete Response Letter (CRL) received in October 2010.
DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.
› Verified 1 days ago
| Entity Name | Orthopedic Centers Of Colorado |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801339502 PECOS PAC ID: 2365714540 Enrollment ID: O20170823001317 |
News Archive
Patients and their physicians should be careful when selecting a chemotherapy drug to treat colorectal cancer that has spread to the liver, say researchers at The University of Texas M. D. Anderson Cancer Center in Houston.
Some of us who are hospitalized are feeling worse rather than better. On average, seven percent of all patients in industrial countries are affected by "nosocomial" infections. In intensive care units, the risk increases even more. This can result in serious illnesses and life-threatening blood poisoning.
A scientist at Leeds whose research is challenging conventional thinking on how the cholesterol-reducing drugs statins benefit cardiac patients, has secured funding to further investigate her findings.
Alexza Pharmaceuticals, Inc. announced today that it completed an End-of-Review meeting with the U.S. Food and Drug Administration (FDA or Agency) for the AZ-004 New Drug Application (NDA), and has received the official FDA minutes from the meeting. In December 2010, Alexza held the End-of-Review meeting in response to a Complete Response Letter (CRL) received in October 2010.
DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.
› Verified 1 days ago
| Entity Name | Platte Valley Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275283574 PECOS PAC ID: 5890054100 Enrollment ID: O20180112000840 |
News Archive
Patients and their physicians should be careful when selecting a chemotherapy drug to treat colorectal cancer that has spread to the liver, say researchers at The University of Texas M. D. Anderson Cancer Center in Houston.
Some of us who are hospitalized are feeling worse rather than better. On average, seven percent of all patients in industrial countries are affected by "nosocomial" infections. In intensive care units, the risk increases even more. This can result in serious illnesses and life-threatening blood poisoning.
A scientist at Leeds whose research is challenging conventional thinking on how the cholesterol-reducing drugs statins benefit cardiac patients, has secured funding to further investigate her findings.
Alexza Pharmaceuticals, Inc. announced today that it completed an End-of-Review meeting with the U.S. Food and Drug Administration (FDA or Agency) for the AZ-004 New Drug Application (NDA), and has received the official FDA minutes from the meeting. In December 2010, Alexza held the End-of-Review meeting in response to a Complete Response Letter (CRL) received in October 2010.
DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Robert Possley, DO 3455 Lutheran Pkwy Ste 105, Wheat Ridge, CO 80033-6028 Ph: (303) 665-2603 | Dr Daniel Robert Possley, DO 340 Exempla Cir Ste 300, Lafayette, CO 80026-3384 Ph: (303) 673-1390 |
News Archive
Patients and their physicians should be careful when selecting a chemotherapy drug to treat colorectal cancer that has spread to the liver, say researchers at The University of Texas M. D. Anderson Cancer Center in Houston.
Some of us who are hospitalized are feeling worse rather than better. On average, seven percent of all patients in industrial countries are affected by "nosocomial" infections. In intensive care units, the risk increases even more. This can result in serious illnesses and life-threatening blood poisoning.
A scientist at Leeds whose research is challenging conventional thinking on how the cholesterol-reducing drugs statins benefit cardiac patients, has secured funding to further investigate her findings.
Alexza Pharmaceuticals, Inc. announced today that it completed an End-of-Review meeting with the U.S. Food and Drug Administration (FDA or Agency) for the AZ-004 New Drug Application (NDA), and has received the official FDA minutes from the meeting. In December 2010, Alexza held the End-of-Review meeting in response to a Complete Response Letter (CRL) received in October 2010.
DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.
› Verified 1 days ago
Dr. Julie A Melchior, Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 280 Exempla Cir, Department Of Orthopaedics, Lafayette, CO 80026 Phone: 303-338-4545 | |
Debra Turski, Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 280 Exempla Cir, Lafayette, CO 80026 Phone: 303-861-3408 | |
Dr. Lance R Little, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 280 Exempla Cir, Lafayette, CO 80026 Phone: 303-338-4545 | |
Dr. Peter P Chiang, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 280 Exempla Cir, Lafayette, CO 80026 Phone: 303-338-4545 | |
Dr. Dimitrios J Zaronias, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 280 Exempla Cir, Lafayette, CO 80026 Phone: 303-338-4545 | |
Dr. George G Robinson Ii, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 280 Exempla Cir, Lafayette, CO 80026 Phone: 303-338-4545 |